Harbor Capital Advisors Inc. Buys 12,797 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Harbor Capital Advisors Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 113.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,093 shares of the medical instruments supplier's stock after purchasing an additional 12,797 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.11% of LeMaitre Vascular worth $2,238,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of LMAT. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 199 shares in the last quarter. West Oak Capital LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at $58,000. USA Financial Formulas acquired a new stake in LeMaitre Vascular during the 3rd quarter valued at $60,000. Finally, nVerses Capital LLC grew its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock valued at $66,000 after acquiring an additional 200 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the company's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company's stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Trading Up 2.4 %

LMAT traded up $2.28 during midday trading on Tuesday, hitting $98.63. 211,550 shares of the company were exchanged, compared to its average volume of 124,154. LeMaitre Vascular, Inc. has a 1-year low of $47.72 and a 1-year high of $101.67. The company's 50 day simple moving average is $89.88 and its 200 day simple moving average is $83.74. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 53.90, a price-to-earnings-growth ratio of 2.38 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the prior year, the company posted $0.33 EPS. The company's quarterly revenue was up 15.6% on a year-over-year basis. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.65%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

Analyst Ratings Changes

Several analysts have recently weighed in on LMAT shares. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price for the company. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a "buy" rating and a $105.00 price objective for the company. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday. Finally, JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.